EE9800329A - Arüülaminorühmaga liidetud püridiinid ja pürimidiinid - Google Patents

Arüülaminorühmaga liidetud püridiinid ja pürimidiinid

Info

Publication number
EE9800329A
EE9800329A EE9800329A EE9800329A EE9800329A EE 9800329 A EE9800329 A EE 9800329A EE 9800329 A EE9800329 A EE 9800329A EE 9800329 A EE9800329 A EE 9800329A EE 9800329 A EE9800329 A EE 9800329A
Authority
EE
Estonia
Prior art keywords
pyridines
pyrimidines
attached
arylamino group
arylamino
Prior art date
Application number
EE9800329A
Other languages
English (en)
Estonian (et)
Inventor
Georgios Arvanitis Argyrios
Avonn Cain Gary
John Chorvat Robert
Joseph Gilligan Paul
Eric Olson Richard
Bakthavatchalam Rajagopal
Peter Beck James
Original Assignee
The Du Pont Merck Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Du Pont Merck Pharmaceutical Company filed Critical The Du Pont Merck Pharmaceutical Company
Publication of EE9800329A publication Critical patent/EE9800329A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EE9800329A 1996-03-27 1997-03-25 Arüülaminorühmaga liidetud püridiinid ja pürimidiinid EE9800329A (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1415796P 1996-03-27 1996-03-27
US64661296A 1996-05-08 1996-05-08
US3053696P 1996-10-31 1996-10-31
US3912497P 1997-02-25 1997-02-25
PCT/US1997/004852 WO1997035539A2 (en) 1996-03-27 1997-03-25 Arylamino fused pyridines and pyrimidines

Publications (1)

Publication Number Publication Date
EE9800329A true EE9800329A (et) 1999-06-15

Family

ID=27486365

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800329A EE9800329A (et) 1996-03-27 1997-03-25 Arüülaminorühmaga liidetud püridiinid ja pürimidiinid

Country Status (21)

Country Link
US (2) US6107300A (de)
EP (1) EP0935601A4 (de)
JP (1) JP2002515032A (de)
KR (1) KR20000005037A (de)
CN (1) CN1230184A (de)
AU (1) AU2545897A (de)
BR (1) BR9708261A (de)
CA (1) CA2250241A1 (de)
CZ (1) CZ304098A3 (de)
EA (1) EA199800868A1 (de)
EE (1) EE9800329A (de)
HR (1) HRP970173A2 (de)
HU (1) HUP9902340A3 (de)
IL (1) IL126316A0 (de)
LV (1) LV12262B (de)
NO (1) NO984418L (de)
NZ (1) NZ331874A (de)
PL (1) PL335258A1 (de)
SI (1) SI9720026A (de)
SK (1) SK131798A3 (de)
WO (1) WO1997035539A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7296896A (en) 1995-11-01 1997-05-22 Novartis Ag Purine derivatives and processes for their preparation
EP0968210A1 (de) * 1997-03-21 2000-01-05 Du Pont Pharmaceuticals Company Verfahren zur herstellung von triazolopyridinen
AU8181098A (en) * 1997-07-03 1999-01-25 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
AU2881199A (en) * 1998-02-26 1999-09-15 Neurogen Corporation Substituted 1,4-dihydro-4-oxonicotinic carboxamides: gaba brain receptor ligands
ES2180338T3 (es) 1998-11-12 2003-02-01 Neurocrine Biosciences Inc Antagonistas del receptor de crf y metodos relacionados.
PT1129096E (pt) 1998-11-12 2003-09-30 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
PL354784A1 (en) 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
AU2583901A (en) * 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
JP2003531111A (ja) * 1999-12-17 2003-10-21 アライアッド・ファーマシューティカルズ・インコーポレーテッド プロトンポンプインヒビター
AU2001232271A1 (en) * 2000-02-14 2001-08-20 Japan Tobacco Inc. Preventives/remedies for postoperative stress
WO2002006286A2 (en) * 2000-07-14 2002-01-24 Bristol-Myers Squibb Pharma Company IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DE60206363T2 (de) 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
NZ528207A (en) 2001-03-13 2006-02-24 Bristol Myers Squibb Pharma Co 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
CN1527710A (zh) 2001-05-14 2004-09-08 ����˹�ж�-����˹˹����ҩƷ��˾ 作为促肾上腺皮质激素释放因子配体的取代的吡嗪酮、吡啶和嘧啶
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
WO2003005969A2 (en) 2001-07-12 2003-01-23 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
US7276526B2 (en) 2001-07-13 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
GB0117525D0 (en) 2001-07-19 2001-09-12 Procter & Gamble Solvent welding process
GB0117522D0 (en) 2001-07-19 2001-09-12 Procter & Gamble Solvent welding process
AU2002340405A1 (en) 2001-11-20 2003-06-10 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
US9967633B1 (en) 2001-12-14 2018-05-08 At&T Intellectual Property I, L.P. System and method for utilizing television viewing patterns
WO2003051881A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US20050065171A1 (en) * 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
AU2004272437A1 (en) * 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
EP2210607B1 (de) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs
EP1720877A4 (de) * 2004-03-02 2009-11-04 Neurogen Corp Arylsubstituierte purinanaloga
EP1598354A1 (de) * 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Durch kondensierten zyklus verbundenen n-heteroaryl verbindungen und ihre verwendung als nad(p)h oxidase und blutplättchen-aggregation hemmer
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
ES2438017T3 (es) * 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
EP1846410B1 (de) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydrochinazolinone als 5ht-modulatoren
EP1703668A1 (de) * 2005-03-18 2006-09-20 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO System zum Verarbeiten von Dienstleistungs (QoS)-Parametern in einem Kommunikationsnetzwerk
AU2006313456B2 (en) * 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
KR101378716B1 (ko) * 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
KR20080034171A (ko) * 2005-07-28 2008-04-18 브리스톨-마이어스 스큅 컴퍼니 세로토닌 수용체 효능제 및 길항제로서의 치환된테트라히드로-1ｈ-피리도[4,3,ｂ]인돌
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
RU2425834C2 (ru) * 2005-11-08 2011-08-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ТИАЗОЛО[4,5-c]ПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ mGluR5
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
AR060061A1 (es) * 2006-03-22 2008-05-21 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa
US20080004253A1 (en) * 2006-06-30 2008-01-03 Bryan James Branstetter Thiazolopyrimidine modulators of TRPV1
EP2081434A2 (de) 2006-10-31 2009-07-29 Janssen Pharmaceutica N.V. Triazolpyrimidinderivate als adp-p2y12-rezeptorantagonisten
JP2010508350A (ja) * 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
NZ578096A (en) * 2007-01-10 2011-11-25 Albany Molecular Res Inc 5-pyridinone substituted indazoles
CN101861311A (zh) * 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
NZ588355A (en) * 2008-03-05 2012-03-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
US8273900B2 (en) * 2008-08-07 2012-09-25 Novartis Ag Organic compounds
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
EP3134405B1 (de) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
CA2976258C (en) * 2015-02-18 2024-02-20 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2017035528A1 (en) * 2015-08-27 2017-03-02 Nantneuro, Llc Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
CA3103048A1 (en) * 2018-06-21 2019-12-26 Janssen Pharmaceutica Nv Oga inhibitor compounds
AU2019319740A1 (en) * 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
US4076711A (en) * 1976-04-05 1978-02-28 Schering Corporation Triazolo [4,5-d]-pyrimidines
EP0155911A1 (de) * 1984-03-19 1985-09-25 Ciba-Geigy Ag Purinderivate zur Regulierung des Pflanzenwachstums
GB8408615D0 (en) * 1984-04-04 1984-05-16 Wellcome Found Heterocyclic compounds
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US5175273A (en) * 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
US5240937A (en) * 1990-04-20 1993-08-31 Burroughs Wellcome Co. Pharmaceutically active triazolopyridine compounds
CA2100863A1 (en) * 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
HUT69705A (en) * 1991-11-25 1995-09-28 Pfizer Indole derivatives
DE69324244T2 (de) * 1992-01-06 1999-09-30 The Wellcome Foundation Ltd., Greenford Therapeutische nukleoside der 2',3'-dideoxy-3'-fluor -purin reihe
US5424297A (en) * 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
FI964893A7 (fi) * 1994-06-06 1996-12-05 Pfizer Substituoituja pyratsoleja, jotka ovat aktiivisia kortikotropiinin vap auttamistekijän (CRF) antagonisteina
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
DK0765327T3 (da) * 1994-06-16 1999-11-29 Pfizer Pyrazolo- og pyrrolopyridiner
EP0770080B1 (de) * 1995-05-12 1999-07-14 Neurogen Corporation Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
PT778277E (pt) * 1995-12-08 2003-11-28 Pfizer Derivados heterociclicos substituidos como antagonistas do crf

Also Published As

Publication number Publication date
NO984418D0 (no) 1998-09-22
US6107300A (en) 2000-08-22
US6448261B1 (en) 2002-09-10
NO984418L (no) 1998-11-03
NZ331874A (en) 2000-03-27
EP0935601A4 (de) 2002-08-07
IL126316A0 (en) 1999-05-09
HUP9902340A3 (en) 2001-02-28
EP0935601A2 (de) 1999-08-18
CA2250241A1 (en) 1997-10-02
HRP970173A2 (en) 1999-08-31
SK131798A3 (en) 2000-05-16
BR9708261A (pt) 2001-12-04
EA199800868A1 (ru) 1999-04-29
WO1997035539A3 (en) 1999-05-14
KR20000005037A (ko) 2000-01-25
WO1997035539A2 (en) 1997-10-02
CZ304098A3 (cs) 1999-02-17
CN1230184A (zh) 1999-09-29
LV12262B (en) 1999-10-20
SI9720026A (sl) 1999-04-30
PL335258A1 (en) 2000-04-10
AU2545897A (en) 1997-10-17
LV12262A (lv) 1999-04-20
JP2002515032A (ja) 2002-05-21
HUP9902340A2 (hu) 1999-11-29

Similar Documents

Publication Publication Date Title
EE9800329A (et) Arüülaminorühmaga liidetud püridiinid ja pürimidiinid
DE69738197D1 (de) Azolotriazine und pyrimidine
FI972087A7 (fi) Dihydropyrimidiineja ja niiden käyttöjä
ID17948A (id) Piridine bersumbu heterosiklik
FR11C0020I2 (fr) Dérives difluoroprostaglandines et leur application
FI970150A7 (fi) Substituoituja pyrimidiiniyhdisteitä ja niiden käyttö
ID23889A (id) Turunan-turunan piridina
ATE302200T1 (de) Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
ATE194832T1 (de) 2-aryl-substituierte pyridine
FI963126L (fi) Stanoliseos ja sen käyttö
ID17659A (id) Piridin campuran-bisiklik
DK1015444T3 (da) Pyrimidinderivater og fremgangsmåder til fremstilling deraf
PL337645A1 (en) Novel amidine derivatives and their application as thrombosin inhibitors
DE69716062D1 (de) Benzofuran-derivate und deren verwendung
EE200000094A (et) Uued plokk-kopolümeerid ja nende saamine
ID24610A (id) Radas serta metode untuk mengkristalisasian
BR1100834A (pt) Piridopirimidinas substituìdas e antihipertensivos
ZA971896B (en) Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
DE69835007D1 (de) Entkoffeinierte mate-extrakte und deren verwendung
EP0901476A4 (de) Aryloxy- und arylthio-verknüpfte Pyridine und Pyrimidine, sowie Derivate davon
FI960994L (fi) Erotuslaite ja siinä olevia komponentteja
NO315610B3 (no) Azolotriaziner og -pyrimidiner
FI972795L (fi) Pyrimidiinijohdannaisia
FR2749049B1 (fr) Embrayage modulaire et sa structure
PT819690E (pt) 6-tienil e 4-tienil pirimidinas herbicidas